H
Howard S. Yeh
Researcher at Amgen
Publications - 29
Citations - 2011
Howard S. Yeh is an academic researcher from Amgen. The author has contributed to research in topics: Denosumab & Zoledronic acid. The author has an hindex of 13, co-authored 29 publications receiving 1860 citations.
Papers
More filters
Journal ArticleDOI
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
David H. Henry,Luis Costa,François Goldwasser,Vera Hirsh,Vania Hungria,Jana Prausova,Giorgio V. Scagliotti,Harm Sleeboom,Andrew Spencer,Saroj Vadhan-Raj,Roger von Moos,Wolfgang Willenbacher,Penella J. Woll,Jianming Wang,Qi Jiang,Susie Jun,Roger Dansey,Howard S. Yeh +17 more
TL;DR: Denosumab was noninferior (trending to superiority) to ZA in preventing or delaying first on-study SRE in patients with advanced cancer metastatic to bone or myeloma and represents a potential novel treatment option with the convenience of subcutaneous administration and no requirement for renal monitoring or dose adjustment.
Journal ArticleDOI
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.
David H. Henry,Saroj Vadhan-Raj,Vera Hirsh,Roger von Moos,Vania Hungria,Luis Costa,Penella J. Woll,Giorgio V. Scagliotti,Geoffrey Smith,Amy Feng,Susie Jun,Roger Dansey,Howard S. Yeh +12 more
TL;DR: Denosumab was more effective in delaying or preventing SREs in patients with bone metastases from solid tumors and also prevented pain progression compared to ZA in this ad hoc analysis.
Journal ArticleDOI
Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure.
Jean-Jacques Body,Allan Lipton,Julie R. Gralow,Guenther G. Steger,Guozhi M. Gao,Howard S. Yeh,Karim Fizazi +6 more
TL;DR: Denosumab suppresses bone resorption markers independently of prior BP treatment, even in patients who appear to respond poorly to BPs, and appeared to be well tolerated in both studies.
Journal ArticleDOI
A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
TL;DR: The ABC regimen was well tolerated by most patients, and it produced preliminary signs of efficacy with an objective response rate of 27% in this heavily pretreated study population, warranting further clinical evaluation of the ABC combination for treatment of relapsed/refractory multiple myeloma.
Journal ArticleDOI
An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma.
Ravi Vij,Noemi Horvath,Andrew Spencer,Kerry Taylor,Saroj Vadhan-Raj,Robert Vescio,Judy Smith,Yi Qian,Howard S. Yeh,Susie Jun +9 more
TL;DR: It is demonstrated that no subjects in either cohort met the protocol‐defined objective response criteria of complete response (CR) or partial response (PR), but that denosumab effectively inhibited the RANKL pathway regardless of previous exposure to bisphosphonates, as evidenced by suppressed levels of the bone turnover marker, serum C‐terminal telopeptide of type 1 collagen (sCTx).